Company profile
Biogen
Neurology + immunology
Share price · BIIB
$212.55+20.64 (+10.76%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(16 total)
16Total Assets
9Approved
2Phase 3 / Filed
5Phase 1–2 / Early
7Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Dimethyl fumarate (Tecfidera)(Tecfidera) | Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis |
Diroximel fumarate(Vumerity) | Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis |
| Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis | |
| Approved | Interferon beta receptor (type I IFN signaling) · Type I interferon receptorBiologic — subtype unspecified | Multiple Sclerosis | |
Lecanemab(Leqembi) | Approved | Amyloid-beta (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease |
natalizumab(Tysabri) | Approved | α4 integrinMonoclonal antibody | Inflammatory Bowel DiseaseMultiple Sclerosis Crohn's Disease |
Pegcetacoplan(Empaveli) | Approved | Complement C3Small molecule | Chronic Kidney Disease |
Pegcetacoplan ophthalmic(Syfovre) | Approved | Complement C3 · Complement C3 / C3bPeptide | Age-Related Macular Degeneration |
peginterferon beta-1a(Plegridy) | Approved | Type I interferon receptor · Interferon beta receptor (type I IFN signaling)Biologic — subtype unspecified | Multiple Sclerosis |
| Phase 3 | LRRK2Small molecule | Parkinson's Disease | |
| Phase 3 | BDCA2 (CLEC4C) · BDCA2 / CD303 (blood dendritic cell antigen 2)Monoclonal antibody | Systemic Lupus Erythematosus | |
| Phase 2 | Bruton's tyrosine kinase (BTK) | Multiple Sclerosis | |
| Phase 2 | Undisclosed / early pipeline | Indication not yet linked | |
| Phase 2 | MAPT mRNA (RNAi/ASO)RNA / oligonucleotide | Alzheimer's Disease | |
| Phase 2 | Type I interferon receptor | Multiple Sclerosis |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.